Management of cirrhosis complications in HIV patients coinfected with hepatitis B or C virus;Prise en charge des complications de la cirrhose chez les patients VIH co-infectés par une hépatite virale B ou C

Presse Medicale

Volumn 34, Issue 20 II, 2005, Pages 1579-1583

  Sogni, P ^a,b   Salmon Ceron D ^a   Podevin, P ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ECHOGRAPHY; GASTROINTESTINAL ENDOSCOPY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LACTIC ACIDOSIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; NON INVASIVE MEASUREMENT; PATIENT CARE; PORTAL HYPERTENSION; PRESCRIPTION; PROPHYLAXIS; PROTEIN DETERMINATION; REVIEW; SCORING SYSTEM; SCREENING TEST; SUPERINFECTION; TREATMENT INDICATION; VIRUS HEPATITIS;

EID: 29444442271     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84228-9     Document Type: Short Survey

References (36)

1. Hamers F, Downs AM. The changing face of the HIV epidemic in western Europe: what are the implications for public health policies? Lancet 2004; 364: 83-94.
2. Soriano V, Garcia-Samaniego J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 1-4.
3. Puoti M, Spinetti A, Ghezzi A. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Synd 2000; 24: 211-17.
4. Bica I, McGovern B, Dhar R. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-7.
5. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467-71.
6. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-14.
7. Rosenthal E, Pialoux G, Rey D. Liver-related mortality in human immunodeficiency virus-infected patients in France (Germivic Cohort Study 1995-2003). Hepatology 2004; 40: 413A.
8. 1st European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV co-infected Patients. J Hepatol 2005; 41: 677-83.
9. Quereda C, Moreno S, Moreno L. The role of liver biopsy in the management of chronic hepatitis C in patients infected with the human immunodeficiency virus. Hum Pathol 2004; 35: 1083-7.
10. Myers RP, Benhamou Y, Imbert-Bismut F. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17: 721-5.
11. Complications de l'hypertension portale chez l'adulte. Recommandations. Gastroenterol Clin Biol 2004; 28: B324-34.
12. Hoofnagle JH. Hepatocellular carcinoma: summary and recommendations. Gastroenterology 2004; 127: S319-23.
13. Moreau R, Lebrec D. Acute renal failure in ptients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 37: 233-43.
14. Salmon-Ceron D, Taburet AM. Utilisation des anti-rétroviraux chez le patient cirrhotique infecté par le VIH. Presse Med 2005; 34 (suppl.1): 45-52.
15. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Elevated enzymes following initiation of antiretroviral therapy. JAMA 2000; 283: 2526-7.
16. Styrt BA, Piazza-Hepp TD, Chikami GK. Clinical toxicity of antiretroviral nucleoside analogs. Antiviral Research 1996; 31: 121-35.
17. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2: 812-22.
18. Rockstroh J, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004; 4: 437-44.
19. Carrat F, Bani-Sadr F, Pol S. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
20. Torriani FJ, Rodriguez-Torres M, Rockstroh JK. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
21. Mauss S, Valenti W, DePamphilis J. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18: F21-5.
22. Murphy MJ, Wilcox RD. Management of the coinfected patient: human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C. Am J Med Sci 2004; 328: 26-36.
23. Garcia-Samaniego J, Rodrigues M, Berenguer J. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-83.
24. Bräu N, Xiao P, Trikha A. Hepatocellular carcinoma in HIV-infected patients and influence of HIV viral load on survival. A multicenter study. Hepatology 2004; 40: 308A.
25. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
26. Forns X, Ampurdanes S, Llovet J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
27. Wai CT, Greenson JK, Fontana RJ. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
28. Patel K, Gordon S, Jacobson I. Evaluation of a panel of non-invasive serum markers to differenciate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41: 935-42.
29. Rosenberg WM, Voelker M, Thiel R. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004; 127: 1704-13.
30. Ziol M, Handra-Luca A, Kettaneh. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
31. Castera L, Vergniol J, Foucher J. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
32. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75: 425-9.
33. Morris S, Taylor C, Muiesan P, Portmann B. Outcomes of liver transplantation in HIV-infected individuals: The impact of HCV and HBV infection. Liver Transplantation 2004; 10: 1271-8.
34. Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transplantation 2004; 10: S39-53.
35. Rufi G, Barcena R, Vargas V, Valdivieso A, Miro JM, Salcedo M et al. Orthotopic liver transplantation in 15 HIV-1-infected recipients: Evaluation of Spanish experience in the HAART era (2002-2003). 11th CROI 2004 (February 8-11).
36. Duclos-Vallee J, Vittecoq D, Teicher E. Experience of liver tranplantation (LT) in 20 HIV-HCV co-infected patients in the highly active antiretroviral (Haart) era 2000-2004. Hepatology 2004; 40: 192A.